Provectus Biopharmaceuticals IncOTCQB:PVCT
- LAST PRICE0.1134
- TODAY'S CHANGE (%)0.0047 (4.2855%)
- Bid / Lots0.1068/ 92
- Ask / Lots0.1149/ 50
- Open / Previous Close0.1061 / 0.1087
- Day Range
- 52 Week Range
- Volume517,506
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PVCT |
|---|---|---|
| 09:32 ET | 16100 | 0.10629 |
| 10:11 ET | 5000 | 0.1099 |
| 10:24 ET | 630 | 0.1088 |
| 10:38 ET | 14000 | 0.1075 |
| 10:51 ET | 573 | 0.10971 |
| 10:54 ET | 181 | 0.1061 |
| 10:56 ET | 267 | 0.10971 |
| 11:00 ET | 1550 | 0.1061 |
| 11:02 ET | 8000 | 0.108 |
| 11:05 ET | 2636 | 0.108635 |
| 12:01 ET | 40100 | 0.1123 |
| 12:21 ET | 1000 | 0.1149 |
| 12:24 ET | 100000 | 0.1125 |
| 01:02 ET | 20000 | 0.1125 |
| 02:30 ET | 196708 | 0.1125 |
| 02:38 ET | 5000 | 0.11434 |
| 02:57 ET | 100192 | 0.1125 |
| 03:53 ET | 3400 | 0.11 |
| 04:00 ET | 2000 | 0.1134 |
Oct 24, 2024
Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Provectus Biopharmaceuticals Inc | 45.7M | -17.1x | --- |
Vyne Therapeutics Inc | 44.5M | -3.5x | --- |
Serina Therapeutics Inc | 46.8M | -0.5x | --- |
CEL-SCI Corp | 44.3M | -1.2x | --- |
CalciMedica Inc | 47.1M | -1.9x | --- |
Intensity Therapeutics Inc | 44.1M | -3.1x | --- |
Company Information
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
Contact Information
- Headquarters
- 800 S. Gay Street, Suite 1610KNOXVILLE, TN, United States 37929
- Phone
- 865-769-4011
- Fax
- 302-674-5266
Executives
- Chairman of the Board, Chief Executive Officer
- Edward Pershing
- President, Vice Chairman of the Board, Principal Executive Officer
- Dominic Rodrigues
- Chief Financial Officer
- Heather Raines
- Chief Technology Officer
- Eric Wachter
- Independent Director
- Webster Bailey
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $45.7M |
|---|---|
Revenue (TTM) | $683.9K |
Shares Outstanding | 419.9M |
Provectus Biopharmaceuticals Inc does not pay a dividend. | |
Beta | 0.59 |
EPS | $-0.01 |
Book Value | $-0.02 |
P/E Ratio | -17.1x |
Price/Sales (TTM) | 66.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -374.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
